What medicine is Rezlidhia (Olutasidenib)?

Rezlidhia (Olutasidenib) is a prescription drug used to treat adults with acute myeloid leukemia (AML), which has a specific gene mutation called IDH1. IDH1 mutations prevent immature blood cells in the bone marrow from developing into healthy mature blood cells. Rezlidhia contains olutasidenib, which belongs to a class of drugs called isocitrate dehydrogenase-1 (IDH1) inhibitors. It treats acute myeloid leukemia by blocking the activity of the protein produced by IDH1. It's not known whether this drug is safe and effective in children.

Rezlidhia is used to treat acute myeloid leukemia (a rapidly growing cancer of bone marrow and blood cells) when the disease relapses or is refractory (stops responding to treatment) due to IDH1 mutations. In acute myeloid leukemia, mutations cause myeloblasts (immature blood cells formed in the bone marrow) to grow and divide uncontrollably. Mutations in the IDH1 gene lead to the accumulation of 2-hydroxyglutarate (2-HG). Increased levels of 2-HG interfere with the process by which immature blood cells turn into mature cells. Rezlidhia inhibits mutated IDH1, thereby reducing 2-HG levels and restoring normal differentiation of myeloid cells.

Rezlidhia can be taken with a high-fat meal. The ingredient in Rezlidhia, olutasidenib, increases drug exposure, so take it on an empty stomach at least 1 hour before or 2 hours after a meal. After Rezlidhia is approved for marketing, there is little information about its price and other related information. Please consult the medical consultant for details.